Zacks places share value of abvc biopharma at $9.50

Fremont, ca, july 06, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the zacks small-cap research report dated june 7, 2022 values abvc at $9.50 per share based upon a financial projection and a series of assumptions in the update.
ABVC Ratings Summary
ABVC Quant Ranking